319 related articles for article (PubMed ID: 28415741)
1. Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.
Gravina GL; Mancini A; Mattei C; Vitale F; Marampon F; Colapietro A; Rossi G; Ventura L; Vetuschi A; Di Cesare E; Fox JA; Festuccia C
Oncotarget; 2017 May; 8(18):29865-29886. PubMed ID: 28415741
[TBL] [Abstract][Full Text] [Related]
2. Radiosensitization by the novel DNA intercalating agent vosaroxin.
Gordon IK; Graves C; Kil WJ; Kramp T; Tofilon P; Camphausen K
Radiat Oncol; 2012 Feb; 7():26. PubMed ID: 22369205
[TBL] [Abstract][Full Text] [Related]
3. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
Festuccia C; Mancini A; Colapietro A; Gravina GL; Vitale F; Marampon F; Delle Monache S; Pompili S; Cristiano L; Vetuschi A; Tombolini V; Chen Y; Mehrling T
J Hematol Oncol; 2018 Feb; 11(1):32. PubMed ID: 29486795
[TBL] [Abstract][Full Text] [Related]
4. The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown
Timme CR; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ
Mol Cancer Ther; 2018 Jun; 17(6):1207-1216. PubMed ID: 29549168
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth.
Inada M; Sato A; Shindo M; Yamamoto Y; Akasaki Y; Ichimura K; Tanuma SI
Anticancer Res; 2019 Dec; 39(12):6743-6750. PubMed ID: 31810939
[TBL] [Abstract][Full Text] [Related]
6. Trifluoperazine, a novel autophagy inhibitor, increases radiosensitivity in glioblastoma by impairing homologous recombination.
Zhang X; Xu R; Zhang C; Xu Y; Han M; Huang B; Chen A; Qiu C; Thorsen F; Prestegarden L; Bjerkvig R; Wang J; Li X
J Exp Clin Cancer Res; 2017 Sep; 36(1):118. PubMed ID: 28870216
[TBL] [Abstract][Full Text] [Related]
7. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
8. The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.
Paubelle E; Zylbersztejn F; Thomas X
Expert Opin Drug Discov; 2017 Jul; 12(7):747-753. PubMed ID: 28504025
[TBL] [Abstract][Full Text] [Related]
9. Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma.
Ferrandon S; Malleval C; El Hamdani B; Battiston-Montagne P; Bolbos R; Langlois JB; Manas P; Gryaznov SM; Alphonse G; Honnorat J; Rodriguez-Lafrasse C; Poncet D
Mol Cancer; 2015 Jul; 14():134. PubMed ID: 26183089
[TBL] [Abstract][Full Text] [Related]
10. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
11. Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
Jamieson GC; Fox JA; Poi M; Strickland SA
Drugs; 2016 Sep; 76(13):1245-1255. PubMed ID: 27484675
[TBL] [Abstract][Full Text] [Related]
12. Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.
Gordon IK; Lu J; Graves CA; Huntoon K; Frerich JM; Hanson RH; Wang X; Hong CS; Ho W; Feldman MJ; Ikejiri B; Bisht K; Chen XS; Tandle A; Yang C; Arscott WT; Ye D; Heiss JD; Lonser RR; Camphausen K; Zhuang Z
Mol Cancer Ther; 2015 Jul; 14(7):1540-1547. PubMed ID: 25939762
[TBL] [Abstract][Full Text] [Related]
13. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.
Pokorny JL; Calligaris D; Gupta SK; Iyekegbe DO; Mueller D; Bakken KK; Carlson BL; Schroeder MA; Evans DL; Lou Z; Decker PA; Eckel-Passow JE; Pucci V; Ma B; Shumway SD; Elmquist WF; Agar NY; Sarkaria JN
Clin Cancer Res; 2015 Apr; 21(8):1916-24. PubMed ID: 25609063
[TBL] [Abstract][Full Text] [Related]
15. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
[TBL] [Abstract][Full Text] [Related]
17. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
19. Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks.
Hawtin RE; Stockett DE; Wong OK; Lundin C; Helleday T; Fox JA
Oncotarget; 2010 Nov; 1(7):606-619. PubMed ID: 21317456
[TBL] [Abstract][Full Text] [Related]
20. Vosaroxin induces mitochondrial dysfunction and apoptosis in cervical cancer HeLa cells: Involvement of AMPK/Sirt3/HIF-1 pathway.
Zhao XL; Yu CZ
Chem Biol Interact; 2018 Jun; 290():57-63. PubMed ID: 29800573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
